SODIUM CHLORIDE INJECTION

Sodium Chloride 0.9% Injection, USP in 500 mL units, packaged 24 per case, is being procured under solicitation SPE2DP-26-T-4264 with a requirement for two cases totaling 48 units. The product is regulated by the FDA and must comply with all applicable medical standards including Medical Marking Standard No. 1, which supersedes MIL-STD-129, and must be packaged in sealed unit containers that protect against damage and shipped in commercial exterior containers suitable for safe delivery at the lowest cost to the designated destination. The item has a non-extendable shelf life of 24 months and is classified as a Type I (Code M) item under DLA’s shelf-life requirements. Strict prohibitions against intentional mercury or mercury-containing compounds apply, with limited exceptions for functional uses in batteries, lighting, instruments, sensors, weapon systems, and specific chemical reagents as defined by NAVSEA. Packaging and marking must adhere to MIL-STD-2073-1E and include compliant labeling with the assigned NSN 6505-01-330-6268. Delivery is required FOB destination within 20 days with no variance allowed in quantity. Approved manufacturers include Cardinal Health, Baxter Healthcare Corp, McKesson, B. Braun Medical Inc, ICU Medical Sales, and Tribalco LLC, each with designated part numbers and NDCs. The contract mandates referral through EBS to confirm product eligibility and compliance, with full technical and quality requirements governed by the DLA Master List as of the solicitation issue date. The solicitation closed on July 29, 2026, and is managed by the Department of Defense's Medical Supply Chain Pharmacy FSA.